title: Activation of cytomegalovirus-specific CD8+T-cell response by antibody-mediated peptide-major histocompatibility class I complexes.
abstract: Imposing antigenicity on tumor cells is a key step toward successful cancer-immunotherapy. A cytomegalovirus-derived peptide recombinantly fused to a major histocompatibility class I complex and a monoclonal antibody can be targeted to tumor cells by antibody-mediated delivery and activate a strong and specific CD8+T cell response.
authors.affiliation: ROCHE Pharma Research and Early Development: Large Molecule Research; ROCHE Innovation Center ; Penzberg, Germany.
authors.forename: Martina
authors.initials: M
authors.lastname: Schmittnaegel
authors.affiliation: ROCHE Pharma Research and Early Development: Discovery Oncology; ROCHE Innovation Center ; Zurich, Switzerland.
authors.forename: Christian
authors.initials: C
authors.lastname: Klein
authors.affiliation: ROCHE Pharma Research and Early Development: Discovery Oncology; ROCHE Innovation Center ; Zurich, Switzerland.
authors.forename: Victor
authors.initials: V
authors.lastname: Levitsky
authors.affiliation: ROCHE Pharma Research and Early Development: Large Molecule Research; ROCHE Innovation Center ; Penzberg, Germany.
authors.forename: Hendrik
authors.initials: H
authors.lastname: Knoetgen
keywords: CMV-pp65-specific CD8+ T cells; MHCI restricted T-cell activation; antibody fusion; major histocompatibility class I; targeted T-cell recruiter; viral mimicry on cancer cells